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Objectives: Anatomic segmentectomy is increasingly being considered as a means of achieving an R0 resection
for peripheral, small, stage I non–small-cell lung cancer. In the current study, we compare the results of video-
assisted thoracic surgery (n ¼ 104) versus open (n ¼ 121) segmentectomy in the treatment of stage I non–
small-cell lung cancer.
Methods: A total of 225 consecutive anatomic segmentectomies were performed for stage IA (n ¼ 138) or IB
(n ¼ 87) non–small-cell lung cancer from 2002 to 2007. Primary outcome variables included hospital course,
complications, mortality, recurrence, and survival. Statistical comparisons were performed utilizing the t test
and Fisher exact test. The probability of overall and recurrence-free survival was estimated with the Kaplan-Meier
method, with significance being estimated by the log-rank test.
Results: Mean age (69.9 years) and gender distribution were similar between the video-assisted thoracic surgery
and open groups. Average tumor size was 2.3 cm (2.1 cm video-assisted thoracic surgery; 2.4 cm open). Mean
follow-up was 16.2 (video-assisted thoracic surgery) and 28.2 (open) months. There were 2 perioperative deaths
(2/225; 0.9%), both in the open group. Video-assisted thoracic surgery segmentectomy was associated with
decreased length of stay (5 vs 7 days, P<.001) and pulmonary complications (15.4% vs 29.8%, P¼ .012) com-
pared with open segmentectomy. Overall mortality, complications, local and systemic recurrence, and survival
were similar between video-assisted thoracic surgery and open segmentectomy groups.
Conclusions: Video-assisted thoracic surgery segmentectomy can be performed with acceptable morbidity,
mortality, recurrence, and survival. The video-assisted thoracic surgery approach affords a shorter length of
stay and fewer postoperative pulmonary complications compared with open techniques. The potential benefits
and limitations of segmentectomy will need to be further evaluated by prospective, randomized trials. (J Thorac
Cardiovasc Surg 2009;138:1318-25)
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Over recent years, video-assisted thoracic surgery (VATS)
approaches have gained increased popularity in the perfor-
mance of anatomic lung resections.1,2 VATS lobectomy
techniques have been developed and refined and are associ-
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lengths of stay,6 and greater discharge independence7 com-
pared with open techniques. VATS lobectomy techniques
have been adopted as the preferred approach in many cen-
ters. Long-term results for VATS lobectomy are now avail-
able demonstrating similar morbidity and mortality profiles,
as well as equivalent long-term oncologic efficacy, when
compared with open lobectomy.8,9
To date, limited data exist regarding the application of
VATS techniques in the setting of anatomic segmentectomy.
The purpose of the current study was to compare the perio-
perative outcomes of patients having anatomic segmentec-
tomy by either a VATS or an open approach for stage I
non–small-cell lung cancer (NSCLC). Outcome variables




Approval for this study was provided by the Institutional Review Board
of the University of Pittsburgh (IRB 0408107), and individual patient con-
sent was waived given the retrospective nature of the analysis. A total of 225rgery c December 2009




NSCLC ¼ non–small-cell lung cancer
VATS ¼ video-assisted thoracic surgery
consecutive patients having anatomic segmentectomy for stage I NSCLC
from 2002 to 2008 were identified by the Thoracic Tumor Registry and
from the billing records of the Heart, Lung and Esophageal Surgery Institute
of the University of Pittsburgh Medical Center. Only patients with patho-
logic stage I disease were included in this study. VATS segmentectomy
was performed in 104 patients, with the remaining 121 patients having
anatomic segmentectomy via an open approach (see Appendix E1). Patient
demographics and tumor characteristics are detailed in Table 1.
Preoperative Evaluation
All patients underwent careful preoperative staging with computed to-
mography scan (with or without positron emission tomography) within
6 weeks of surgery as well as pulmonary function testing. Additional diag-
nostic testing (brain magnetic resonance imaging, bone scan) was performed
at the discretion of the individual surgeon, based upon patient symptoms and
clinical findings. Mediastinoscopy was not used routinely in the preopera-
tive evaluation of this group of patients. Flexible bronchoscopy was per-
formed prior to surgical resection in all cases. All patients were staged on
final pathologic review as stage IA (n ¼ 138) or IB (n ¼ 87) according to
the TNM classification of the American Joint Committee for Cancer Staging
and the Revised International System for staging lung cancer.10
Operative Technique and Hospital Course
Thoracotomy was performed in 121 (54%) patients, with a VATS ap-
proach used in 104 (46%) patients. All of the principal anatomic segments
were resected (Table 2). All procedures were performed by 1 of 11 surgeons,
though 167 (74.2%) of the procedures was performed by a single surgeon
(R.J.L.). The largest determinants in selecting a patient for segmentectomy
were limited functional status, comorbidities, and surgeon judgment regard-
ing resectability using a segmental approach.
Open segmental resection was performed by either muscle-sparing axil-
lary thoracotomy or posterolateral minithoracotomy. The VATS approach
was performed as described previously.11,12 Anatomic segmentectomy
was performed with individual isolation and division of the corresponding
artery and bronchus. In addition, an extended parenchymal margin was ob-
tained during stapling, which carried the line of division into the adjacent
segmental parenchyma (extended segmentectomy).
Most patients were monitored in the intensive care unit overnight and
were transferred to the floor the following day. Chest tube management
and discharge planning were individualized based upon patient clinical
characteristics and surgeon judgment. Chest tubes are usually removed
when air leaks cease and drainage decreases to less than 250 mL/d. Patients
were discharged after chest tube removal when clinically stable. In cases of
prolonged air leaks (VATS: 8 [7.7%] vs open: 8 [6.6%]), patients were dis-
charged after placement of a Heimlich valve and ensuring stability of lung
expansion. Discharge criteria were not influenced by clinical pathways or
the type of surgery performed.
Follow-up
Perioperative and follow-up data were collected from the hospital chart,
anesthesia, and operating room records as well as the electronic medical re-
cord for each patient. Major complications were defined to include (1) car-
diac: myocardial infarction and cardiac arrest; (2) pulmonary: pneumonia,
empyema, bronchopleural fistula, respiratory failure requiring reintubation
and tracheostomy; (3) other: septicemia, pulmonary embolism, and stroke.
All patients were followed postoperatively at 2 weeks and at 4- to 6-monthThe Journal of Thoracic andintervals for the first 2 years, then yearly thereafter with computed tomog-
raphy scans. Locoregional recurrence was defined as evidence of tumor
within the same lobe, the hilum, or the mediastinal lymph nodes. Distant re-
currences were defined as evidence of tumor in another lobe or elsewhere
outside the hemithorax. In addition to the data derived from the electronic
medical record and the University of Pittsburgh Lung Cancer Registry,






(n ¼ 121) P value
Age
Mean  SD 69.9  7.9 69.9  10.1 .95
Range 45–100 47–91
Gender 55 M, 49 F 55 M, 66 F .29
Histology
Adenocarcinoma 57 (55%) 70 (57%) .69
Squamous cell
carcinoma
30 (28%) 39 (32%) .66
Large-cell
carcinoma
6 (6%) 3 (2%) .31
Adenosquamous 4 (4%) 4 (3%) .99
Bronchoalveolar 1 (1%) 2 (2%) .99
Other 6 (6%) 3 (2%) .31
Stage
IA 66 (63%) 72 (60%) .58
IB 38 (37%) 49 (40%)
Tumor size .05
Mean  SD (cm) 2.1  1.1 2.4  1.2
Range (cm) 0.5–6.0 0.2–7.0
PFTs (preoperative)
FEV1 (%) 1.83 (69%) 1.74 (71%) .58
DLCO (%) 14.7 (64%) 13.8 (67%) .54
DLCO, Lung diffusion capacity for carbon monoxide; FEV1, forced expiratory volume
in 1 second; PFT, pulmonary function tests; SD, standard deviation; VATS, video-
assisted thoracic surgery.






(n ¼ 121) P value
RUL 22 (21.2%) 42 (34.7%) .03
Anterior 4 (3.8%) 7 (5.8%) .55
Posterior 11 (10.6%) 17 (14.0%) .54
Apical 5 (4.8%) 8 (6.6%) .78
Apicoposterior 2 (1.9%) 10 (8.3%) .04
RML 14 (13.5%) 10 (8.3%) .28
RLL 19 (18.3%) 23 (19.0%) .99
Superior 10 (9.6%) 13 (10.7%) .83
Basilar 9 (8.7%) 10 (8.3%) .99
LUL 35 (33.7%) 31 (25.6%) .19
Upper division 24 (23.1%) 26 (21.5%) .87
Lingula 11 (10.6%) 5 (4.1%) .07
LLL 14 (13.5%) 15 (12.4%) .84
Superior 4 (3.8%) 10 (8.3%) .27
Basilar 10 (9.6%) 5 (4.1%) .11
LLL, Left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle
lobe; RUL, right upper lobe; VATS, video-assisted thoracic surgery.Cardiovascular Surgery c Volume 138, Number 6 1319
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VATS segmentectomy (n ¼ 104) Open segmentectomy (n ¼ 121) P value
Operative time (min) 136 (120–152) 143 (132–154) .42
EBL (mL) 171 (133–209) 220 (171–269) .16
LN harvested 6.4 (5.3–7.5) 9.1 (7.8–10.4) .003
LOS (median), d* 5 (mean ¼ 6.4; 5.5–7.3) 7 (mean ¼ 8.2; 7.3–9.1) <.001
Complications (%)
Overall 27 (26.0%) 41 (33.9%) .24
Major 6 (5.8%) 15 (12.4%) .11
Pulmonary 16 (15.4%) 36 (29.8%) .012
Mortality (30 d) 0 (0%) 2 (1.7%) .50
Results shown are n (95% confidence intervals) or n (%). EBL, Estimated blood loss; LOS, length of stay; LN, lymph nodes. *Percentage of patients with complication type are
expressed in parentheses.mortality data were obtained from the Social Security Death Index. The pri-
mary end points for this analysis were perioperative outcomes, morbidity
and mortality rates, as well as disease-free and overall survival. Periopera-
tive mortality was defined as any patient who died within the first 30 days
after surgery. Mean follow-up was 16.2 months in the VATS segmentec-
tomy group and 28.2 months in the open group.
Statistical Analysis
Comparisons of VATS and open segmentectomy cohorts were per-
formed on the basis of clinical, demographic, and pathologic data. Student
t test and Mann-Whitney test were used to compare the distributions of con-
tinuous data (age, tumor size, number of lymph nodes removed, operative
time, estimated blood loss, length of stay). Fisher exact test was used to
compare the frequencies of categorical measures (sex, histology, stage,
etc). All comparisons were 2-tailed. Disease-free survival was defined as
the time from surgery to the first diagnosis of local, regional, or distant dis-
ease recurrence or until last-follow-up. Overall survival was defined as the
time from surgery to death or last follow-up. Disease-free and overall sur-
vival curves were estimated with the Kaplan-Meier method. Significance
was assessed with the log-rank test.
A propensity-matched analysis was performed comparing outcomes
following VATS and open segmentectomy. Propensity scores were deter-
mined for each patient and were included in the Cox regression analysis in
addition to patient age, gender, comorbidities, preoperative pulmonary func-
tion testing, tumor size, tumor stage, and number of lymph nodes harvested.
RESULTS
Patient and Tumor Characteristics
Patient and tumor characteristics are summarized in
Table 1. There were no significant differences in age, gender,
histology, stage (1A or 1B), tumor size, or pulmonary func-
tion tests between the VATS and open segmentectomy
groups. Adenocarcinoma constituted the most common
pathologic subtype of NSCLC in both groups (VATS ¼
55%, open ¼ 57%), followed by squamous cell carcinoma
(VATS ¼ 28%, open ¼ 32%). The most common segmen-
tal resection performed in both groups was the formal left up-
per-division resection (VATS ¼ 23.1%, open ¼ 21.5%).
The distribution of segmentectomies performed was similar
between groups, except for right upper-lobe apicoposterior
segment (VATS: 1.9% vs open: 8.3%, P ¼ .04; Table 2).
Perioperative Outcomes
The median operative time (VATS ¼ 136 minutes;
open ¼ 143 minutes) and estimated blood loss (VATS ¼1320 The Journal of Thoracic and Cardiovascular S171 mL; open ¼ 220 mL) were similar between VATS
and open segmentectomy groups (Table 3). Fewer lymph
nodes were harvested on average during VATS segmentec-
tomy, compared with open segmentectomy (6.4. vs 9.1,
P ¼ .003). There were 2 perioperative deaths, both in the
open group (1.7%). Median hospital stay was 5 days after
VATS segmentectomy and 7 days after the open approach.
Complications occurred in 68 patients (30.2%) and are out-
lined in Table 4. The most common complication was atrial
fibrillation, which occurred in 17 (9.2%) patients. Prolonged
air leak (>5 days) was encountered in 8 patients in both the
VATS (7.7%) and open (6.6%) groups. There were 2 con-
versions (1.9%) from VATS to open segmentectomy sec-
ondary to intraoperative hemorrhage. There was no
significant difference in overall (26.0% vs 33.9%) or major
complications (5.8 vs 12.4%) comparing VATS and open
segmentectomy, respectively. Pulmonary complications
were more common after open segmentectomy (29.8%
open vs 15.4% VATS; Tables 3 and 4).
Recurrence Patterns and Survival
There were 46 recurrences during the follow-up period
(20.4%): 18 locoregional, 28 distant. Mean time to recur-
rence was 13.8 months. Overall recurrence was similar be-
tween VATS (16.3%) and open (24.0%) groups
(Table 5). There was no difference in recurrence-free
(Figure 1) or overall survival (Figure 2) between VATS
and open segmentectomy groups. Propensity analysis simi-
larly revealed no apparent difference in recurrence-free (P¼
.996) or overall (P ¼ .605) survival.
Overall, there were 13 (12.5%) deaths in the VATS group
and 36 (29.7%) deaths in the open group. Deaths due to can-
cer were similarly increased in the open group (Table 5).
This may be due, in part, to the longer mean follow-up in
the open cohort (VATS ¼ 16.0 months; open ¼ 28.2
months).
DISCUSSION
Though lobectomy remains the gold standard in the man-
agement of NSCLC, there has been a resurgence of interest
in the use of anatomic segmentectomy for early stage lungurgery c December 2009
Schuchert et al General Thoracic Surgery
G
T
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otherwise tolerate lobectomy.13 The use of sublobar resec-
tion has been historically associated with an increased risk
of local recurrence.14,15 Emerging data over the last decade,
however, have suggested that anatomic segmentectomy can
achieve comparable recurrence and survival rates compared
with lobectomy in patients with small (2 cm), peripheral
tumors and when adequate surgical margins can be
obtained.11,16 Limited data are currently available assessing
the potential advantages of VATS techniques in the setting
of anatomic segmentectomy.
Nearly 70 years ago, segmental pulmonary resection was
used for the treatment of bronchiectasis and infectious le-
sions.17,18 Subsequently, surgeons have explored the utility
of this approach for the treatment of early stage NSCLC in
patients with cardiopulmonary compromise.19-21 In the early
1990s, use of anatomic segmentectomy fell out of favor due
to its perceived technical complexity and concerns regarding
increased local recurrence rates compared with lobectomy.22
The Lung Cancer Study group conducted the only random-










Cardiac 11 10 .65
A-fib 10 (9.6%) 7 (5.8%) .32
Cardiac arrest 0 (0%) 2 (1.7%) .5
MI 1 (1.0) 1 (0.8%) .99
Pulmonary 26 49 .016
Air leak 8 (7.7%) 8 (6.6%) .8
Pneumonia 1 (1.0%) 6 (5.0%) .13
Bronchoscopy 3 (2.9%) 10 (8.3%) .095
Pneumothorax 9 (8.2%) 7 (5.8%) .44
Respiratory
failure
2 (1.9%) 8 (6.6%) .11
Tracheostomy 2 (1.9%) 2 (1.7%) .99
Empyema 1 (1.0%) 4 (3.3%) .38
Effusion/drainage 0 (0%) 3 (2.5%) .25
B-P fistula 0 (0%) 1 (0.8%) .99
Infections 3 13 .035
Pneumonia 1 (1.0%) 6 (5.0%) .13
Empyema 1 (1.0%) 4 (2.5%) .38
Clostridium difficile 0 (0%) 1 (0.8%) .99
Wound infection 0 (0%) 0 (0%) .99
Septicemia 1 (1.0%) 2 (1.7%) .99
Other 4 2 .42
PE 0 (0%) 1 (0.8%) .99
Renal failure 0 (0%) 1 (0.8%) .99
CVA 0 (0%) 1 (0.8%) .99
Bleeding/reoperation 1 (1%) 1 (0.8%) .99
DVT 1 (1%) 0 (0%) .46
Total 46 74 .016
A-fib, Atrial fibrillation; B-P fistula, bronchopleural fistula; CVA, cerebrovascular
accident; DVT, deep vein thrombosis; MI, myocardial infarction; PE, pulmonary
embolism; VATS, video-assisted thoracic surgery.The Journal of Thoracic and Caized study comparing sublobar resection with lobectomy for
patients with stage IA NSCLC.14 The principal finding in
this study was a threefold increase in local recurrence
(17.2% vs 6.4%) in patients who had sublobar resection.
Two years later, another prospective, multicenter non-
randomized study demonstrated a similar trend for increased
local recurrence in patients having sublobar resection.15
These and other studies have established lobectomy as the
modern surgical approach of choice in patients with early
stage lung cancer.
The increased identification of small NSCLC tumors by
enhanced computed tomography screening protocols in
higher-risk surgical patients23 has led many surgeons to
question the appropriateness of lobectomy for these tu-
mors.24 Sublobar resections have been demonstrated to
achieve lower perioperative morbidity and mortality
rates25,26 and to preserve pulmonary function compared
with lobectomy,27,28 and may represent the only feasible sur-
gical option in high-risk patients with compromised
cardiopulmonary function. Furthermore, studies from
Japan,28-31 the United States,32,33 and Europe34 have demon-
strated recurrence and survival rates similar to that achieved
by lobectomy for small (<2 cm), peripheral lesions, espe-
cially when adequate surgical margins are obtainable.11,35
Little data currently exist on the use of VATS segmentec-
tomy in the treatment of stage I NSCLC. Roviaro and col-
leagues36 were the first to report a series of thoracoscopic
anatomic lung resections, including a patient treated with
segmentectomy. Several reports including small cohorts of
patients having VATS segmentectomy suggested that this
procedure could be performed safely; however, its oncologic
efficacy remained in question.33,37,38 Houck and associ-
ates39 reported on a series of 11 patients having left upper-
lobe trisegmentectomy using a VATS approach, with no
operative mortality and no evidence of recurrence at 13.5
months. The first report evaluating a larger series of patients
having VATS segmentectomy was published by Shiraishi
and associates in 2004.40 In this study, 34 patients having
VATS segmentectomy were compared with 25 patients hav-
ing open segmentectomy. VATS segmentectomy was asso-
ciated with increased operative times (VATS ¼ 240.2
minutes vs open ¼ 203.5 minutes) as well as decreased






(n ¼ 121) P value
NED 87 (83.7%) 92 (76.0%) .19
Overall 17 (16.3%) 29 (24.0%) .10
Locoregional 5 (4.8%) 13 (10.7%) .14
Distant 12 (11.5%) 16 (13.2%) .84
Total deaths 13 (12.5%) 36 (29.8%) .002
Deaths due to cancer 7 (6.7%) 20 (16.5%) .025
NED, No evidence of disease.rdiovascular Surgery c Volume 138, Number 6 1321
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days). There were similar rates of morbidity between the 2
groups. Atkins and coworkers41 reported a series of 48
patients having thoracoscopic segmentectomy and com-
pared the perioperative outcomes with 29 patients having
open segmentectomy. VATS segmentectomy resulted in
shorter hospital stay (VATS ¼ 4.3 days vs open ¼ 6.8
days) and was associated with improved overall survival
compared with the open group.
In the current study, we evaluated the outcomes of 104 pa-
tients who had VATS segmentectomy for stage I NSCLC
and compared the outcomes with 121 patients having open
segmentectomy. The groups were well matched for age,
gender, histology, stage, and preoperative pulmonary func-
tion (Table 1). In this series, all varieties of segmental resec-
tions were performed in the VATS and open groups (Table
2). Perioperatively, there was no difference in operative time
or estimated blood loss. The principle findings of the current
study were that VATS segmentectomy was associated with
decreased length of stay and decreased pulmonary complica-
tions compared with open segmentectomy (Table 3), with no
difference in recurrence-free or overall survival (Table 5,
Figures 1 and 2). These findings mirror the advantages
that have been documented in VATS lobectomy compared
with the corresponding open approaches.5,6,8,9 There were
no operative deaths in the VATS group, and there was
a significantly lower number of pulmonary complications
(Table 3). Though the total number of deaths and deaths
due to cancer were greater in the open group, this likely
reflects the longer mean follow-up in this group. This con-
tention is supported by the equivalent Kaplan-Meier esti-
FIGURE 1. Recurrence-free overall survival after VATS (gray) and open
(black) segmentectomy. VATS, Video-assisted thoracic surgery.1322 The Journal of Thoracic and Cardiovascular Smates for long-term recurrence-free survival (Figure 2).
Though there was no significant difference in survival
between the VATS and open approaches (Figure 1), the
VATS group demonstrated a trend for early survival advan-
tage within the first 2 years. This finding may be due, in
part, to the decreased pulmonary complications seen perioper-
atively in the VATS group and perhaps to a concomitant
diminished physiologic impact with the VATS approach,
though this is purely speculative. There was an increased num-
ber of late deaths seen in the VATS group (unrelated to tumor
recurrence), which negated this early survival advantage.
The perioperative outcomes with VATS segmentectomy
in this series compare quite favorably with previously pub-
lished open series. The early results of the ACOSOG
Z0030 trial provide important information on the modern-
day mortality and morbidity associated with anatomic lung
resection for NSCLC, including anatomic segmentectomy.42
The mortality (0.9%) and complication rates (26%) of the
current study are comparable to those of Z0030 for open seg-
mentectomy (3% and 46%, respectively).
Tumor size and adequacy of surgical margin have been
previously demonstrated to impact on recurrence risk subse-
quent to anatomic segmentectomy.11,16 Among the 225 pa-
tients having anatomic segmentectomy for stage I NSCLC,
disease recurred in 46 (20.4%): 18 locoregional, 28 distant.
There was no apparent difference in overall (19.7% vs
20.8%) or locoregional recurrence (9.9% vs 6.7%) between
those patients with tumors 2 cm or 2 cm, respectively.
Interestingly, patients with a margin:tumor size ratio>1
had significantly fewer recurrences (14.7%) than those
with a ratio 1 (28.9%, P ¼ .037), underscoring the impor-
tance of maintaining an adequate margin during segmental
resection.
FIGURE 2. Overall survival after VATS (gray) and open (black) segmen-
tectomy. VATS, Video-assisted thoracic surgery.urgery c December 2009
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spective nature of this analysis has the potential for introduc-
ing bias in patient selection and perioperative management.
In addition, this report is derived from the experience of
a single institution with extensive experience in VATS
techniques, thus limiting the general applicability of the re-
ported findings to thoracic surgical practice. Though great
effort was taken to thoroughly identify and report the com-
plications encountered in these groups, the assessment of
complications is always more accurate when compiled pro-
spectively. Due to the more recent employment of VATS
techniques during the study period, follow-up is noted to
be necessarily longer in the open group compared with the
VATS group, thus complicating assessment of recurrence
and survival. When adjusting for follow-up in the VATS
and open groups, however, no significant differences were
seen in postoperative mortality or recurrence.
In our experience, the ideal lesions for VATS anatomic
segmentectomy are small (2 cm) and peripherally located
in the outer third of the lung parenchyma. The lesions should
reside in a delineated segmental boundary, so that an R0 re-
section can be obtained with adequate margins (ideally larger
than the size of the tumor). This technique may be particu-
larly advantageous for elderly patients with impaired cardio-
pulmonary function or in those patients with ground glass
opacities that are associated with low metastatic potential.43
Taken together, these data suggest that the VATS ap-
proach is safe and effective when performing anatomic seg-
mentectomy in experienced centers. Though not directly
assessed in the current analysis, the results of this study dem-
onstrate recurrence and survival curves similar to those seen
following lobectomy for stage I NSCLC. Several recent re-
ports have documented equivalent recurrence and survival
rates when comparing segmentectomy and lobectomy
in the setting of stage I NSCLC,11,16 especially for
tumors<2 cm in size.32 A national, prospective randomized
trial (CALGB 140503) is currently underway comparing lo-
bar versus sublobar (segmentectomy, extended wedge) re-
section for stage I NSCLC. Such randomized data will be
necessary to more precisely and reliably establish the advan-
tages and disadvantages of anatomic segmentectomy
(whether performed VATS or open) in this setting.
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Discussion
Dr Giancarlo Roviaro (Milan, Italy). I would like to thank Dr
Schuchert and coworkers for presenting this good experience in an-
atomic segmentectomies, which once again seems to confirm the
validity of VATS in the treatment of early-stage lung cancer. The
paper is good, well done, and the analysis of the patients, of the out-
comes and of survival, is totally correct. Before asking you my
questions, I would like to make some personal observations regard-
ing the so-called VATS lobectomies and anatomic resections.
When, 17 years ago, I started my experience of thoracoscopic lo-
bectomies, the majority of thoracic surgeons in the United States
(except 10, or maximum 20, and some of them are present here to-
day) were completely against these operations, considering these
operations absurd, catastrophic, and oncologically not correct. In
these years, the technique has surely been improved. Many authors,
in order to reduce the technical difficulties, have presented different
options to perform this operation, and at this moment I don’t know
what a VATS lobectomy really is. I don’t know how many types of1324 The Journal of Thoracic and Cardiovascular SVATS lobectomy exist, and when it’s possible to call them VATS
lobectomies, thoracoscopic lobectomies, or open lobectomies only
because the thoracoscope is introduced with a 10-cm, 15-cm inci-
sion and a wide incision of intercostal muscles using forceps,
Duval, and all the other instrumentation for conventional surgery.
In the literature, many surgeons, with perfect selection of pa-
tients and good experience, have a high conversion rate. On the
other hand, other surgeons don’t have conversions and consider
these so-called VATS lobectomies the ideal operation for every pa-
tient. They also present sleeve lobectomies in this way. Are these
the same operation or must we change the name to avoid the con-
fusion?
In your paper, Dr Schuchert, you have written that, in the early
’90s, the anatomic open segmentectomies fell out of favor due to
technical difficulties. Up to now, open sublobar resections have
been accepted as an appropriate alternative to lobectomy in com-
promised patients. Recently, many authors have presented good re-
sults after wedge resection, similar to those after lobectomy, even
for fit patients.
My question is, when CT scan discovers a peripheral lesion less
than 1 or 2 cm, how do you decide whether to perform a wedge re-
section instead of a segmentectomy or a formal lobectomy? How do
you select the open versus the thoracoscopic approach, and how
many VATS or open lobectomies did you perform in comparison
with 225 segmentectomies?
Dr Schuchert. Thank you, Dr Roviaro, for your comments.
Addressing the first question regarding small lesions, when
1-2 cm nodules are identified and are confined to a specific bron-
chopulmonary segment, we would consider performing an ana-
tomic segmentectomy in an effort to preserve function, especially
in elderly patients or patients in whom lobectomy may be consid-
ered a higher risk option. We generally prefer anatomic segmentec-
tomy over a simple wedge resection because of the concern
regarding an increased local recurrence rate associated with wedges
compared to segments. El-Sherif and colleagues found a 3.8% ver-
sus 14.5% locoregional recurrence rate when comparing anatomic
segmentectomy versus wedge resection (Ann Surg Oncol.
2007;14:2400-5). So when performing a sublobar resection for
small lesions confined to a distinct bronchopulmonary segment,
we would prefer a formal anatomic segmentectomy as opposed to
a wedge. If we encounter a larger lesion (>3 cm) that crosses seg-
mental boundaries, or if N1 lymph node involvement is suspected
or documented, a lobectomy would be advocated.
The second question relates to the open versus VATS approach.
I think a lot of that comes down to technical experience and surgical
judgment. The principal investigators in this study have extensive
experience in VATS techniques and have developed a technical ap-
proach that facilitates resident teaching and is flexible in implemen-
tation, whether performing a segmentectomy or lobectomy. Of
primary importance, great effort is undertaken to avoid compromis-
ing the fundamental principles of the procedure, and to try to emu-
late as specifically as possible the open approach when using the
VATS technique. We use many of the same dissection instruments
and stapling equipment, perform the same type of selective ap-
proach to the hilar structures, and try to achieve the exact same sur-
gical margins that we would under open conditions.
During the same period of this study, our group has performed
approximately 250 lobectomies for pathological stage 1 non–urgery c December 2009
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majority have been performed open. Over recent years, however,
there has been a significant increase in the use of the VATS ap-
proach for lobectomy.
Dr Roviaro. My second question regards the old problem of
lymphadenectomy and videothoracoscopy. Is lymphadenectomy
feasible in the same way as in open surgery, or must we exclude
the patients in which the frozen section during the operation dem-
onstrated N1 or N2? As you know, lymph node enlargement is not
a sure sign of malignancy. On the other hand, small lymph nodes
can be metastatic. Do you always perform a complete lymphade-
nectomy or do you sample each level, or else do you just harvest
local lymph nodes? Does your attitude differ in open or in the vid-
eothoracoscopic approach?
Dr Schuchert. Our group tends to perform systematic lymph
node sampling of the standard stations on each side. We do place
an importance on obtaining an adequate sample from each station.
The results of the ACOSOG Z0030 trial will add important infor-
mation regarding the utility of lymph node dissection versus sam-
pling in the setting of clinical stage 1 non–small-cell lung cancer.
Dr Roviaro. For my last question, in my experience I have per-
formed a limited resection only in very compromised patients. Sur-
vival rates have been significantly decreased due to causes
unrelated to cancer, whereas recurrence was not always a determi-
nant of the decreased survival in these patients. What has been the
impact of non–cancer-related causes on your survival, and, at the
end, why did you operate on a 100-year-old patient?
Dr Schuchert. The majority of deaths in our group were due to
noncancer causes. Those that were due to malignancy were more
commonly associated with disseminated disease. This pattern sup-
ports the notion that a distinct survival advantage might not be at-
tained by doing a more aggressive resection in this select group of
patients in whom the disease exhibits a more systemic biology.
Advanced age is viewed as a relative contraindication in select-
ing patients for surgery. We certainly encounter elderly patients
who are extremely fit. We prefer to focus on a patient’s physiologic
age, their estimated ability to withstand the procedure, and their
personal disposition toward pursuing surgery aggressively. It’s an
individualized decision when choosing to operate on an elderly pa-
tient.
Dr Roviaro. Thank you.
Dr L. Penfield Faber (Chicago, Ill). I saw those indications up
there for segmental resection and I am very pleased to say that I’m
happy I qualify. Dr Jensik and Dr Faber are very pleased to see
that, indeed, there is a renewed interest in segmental resection.
Our first series in 1973 with 65 cases (it was subsequently ex-
panded to over 350 cases) had a mortality rate of 1.6% and a 5-
year actuarial survival rate of 56%. Now, in those days, we didn’t
stage as well as we stage nowadays, and certainly I think if we had
staged better, we had measured the size of the tumor, and taken out
all the lymph nodes that should be taken out, survival would have
been better. But with new techniques, stapling techniques, indeed I
think that morbidity and mortality will be much less. I am a littleThe Journal of Thoracic and Cdisappointed that you reserve it for individuals over the age of 75
because I think the operation you are describing has the potential
to be an operation of choice for the lesion 2 cm and less. We must
remember that, in the lung cancer study group, 40 wedges were
included in that series. The end result was that survival was the
same despite an increase in local recurrence. I would certainly
want to say that a segmentectomy by stapling technique, VATS
technique, should not be a deep wedge resection, and it must be
an anatomic resection—pulmonary artery, pulmonary bronchus,
and lymph node resection.
So my question is, as you are doing your VATS segmentectomy
and you encounter a lymph node at level 11 or level 12 and frozen
section reveals metastatic microcancer, because we’re going to hear
a paper about understaging, what do you do then?
Dr Schuchert. When we encounter a level 11 or 12 lymph node
during the course of dissection, we would definitely consider lobec-
tomy in an effort to obtain an R0 resection. In all surgical resec-
tions, we also carefully assess the standard mediastinal lymph
node stations so that we accurately stage those patients.
Dr Raja Flores (New York, NY). First of all, I want to state that I
am a huge proponent of VATS lobectomy and VATS segmentec-
tomy. However, many surgeons who support open thoracotomy
will frequently state that there is a huge selection bias when we per-
form these studies of open and VATS patients, which leads me to
conversion. The number of patients that you presented, I’m sure
there must have been some conversions in there.
Dr Schuchert. Yes.
Dr Flores. What was your conversion rate from VATS seg-
mentectomy to open segmentectomy and from VATS segmentec-
tomy to VATS lobectomy, and how did you handle that in your
analysis?
Dr Schuchert. There were 2 conversions in this series, both for
bleeding. I do not have the answer as to how many patients started
off as a segmentectomy and went on to lobectomy because the pa-
tients analyzed in this series were only those who ended up being
treated ultimately with segmentectomy. Patients undergoing
a VATS segmentectomy who underwent conversion to an open ap-
proach were included in the VATS cohort because the intention
was to treat via VATS.
Dr Tomasz Grodzki (Szczecin, Poland). I would like to con-
gratulate you on an excellent paper. I think segmentectomy is a sur-
gery of choice for really small tumors. My question regards the time
of surgery. Open segmentectomy took 2½ hours in your hands. My
simple question is, what have you been doing there so long?
Dr Schuchert. Your comments are appreciated. I think a lot of
that is a testament to our faculty’s dedication to teaching and train-
ing young personnel to do this procedure. Anatomic segmentec-
tomy is a procedure that residents do not have as much
experience with compared to lobectomy. There are different ana-
tomic and intraoperative decision-making issues that have to be
considered. Like most minimally invasive procedures, operative
time tends to decrease with surgeon experience.
Dr Grodzki. Thank you.ardiovascular Surgery c Volume 138, Number 6 1325
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